GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (OTCPK:AKESF) » Definitions » Effective Interest Rate on Debt %

Akeso (AKESF) Effective Interest Rate on Debt % : 2.90% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Akeso Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Akeso's annualized positive value of Interest Expense for the quarter that ended in Jun. 2024 was $12.7 Mil. Akeso's average total debt for the quarter that ended in Jun. 2024 was $438.1 Mil. Therefore, Akeso's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2024 was 2.90%.

Akeso Effective Interest Rate on Debt % Historical Data

The historical data trend for Akeso's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso Effective Interest Rate on Debt % Chart

Akeso Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial 5.26 4.69 1.97 3.07 3.54

Akeso Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.84 3.37 3.43 3.52 2.90

Competitive Comparison of Akeso's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Akeso's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akeso's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akeso's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Akeso's Effective Interest Rate on Debt % falls into.


Akeso Effective Interest Rate on Debt % Calculation

Akeso's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -12.183/( (269.534+418.882)/ 2 )
=-1  *  -12.183/344.208
=3.54 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=204.718 + 64.816
=269.534

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=362.157 + 56.725
=418.882

Akeso's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2023 )+Total Debt  (Q: Jun. 2024 ))/ count )
=-1  *  -12.726/( (418.882+457.372)/ 2 )
=-1  *  -12.726/438.127
=2.90 %

where

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=362.157 + 56.725
=418.882

Total Debt  (Q: Jun. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=418.016 + 39.356
=457.372

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is two times the semi-annual (Jun. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Akeso  (OTCPK:AKESF) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Akeso Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Akeso's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Akeso Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (OTCPK:AKESF) » Definitions » Effective Interest Rate on Debt %
Comparable Companies
HKSE:09995 HKSE:01877 HKSE:01548 HKSE:06990 HKSE:01530 HKSE:06826 HKSE:02162 HKSE:01177 HKSE:09969 HKSE:01541 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
09926:Hong Kong 4RY:Germany
Address
6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437
Website
https://www.akesobio.com
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation, and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.